Stock data
NewAmsterdam Pharma Company N.V. (NAMS)
NewAmsterdam Pharma Company N.V. (NAMS) reported revenue of US$22.50M and net income of -US$203.82M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$22.50M | — | -US$225.68M | -US$203.82M | — |
| 2024 | US$45.56M | — | -US$176.29M | -US$241.60M | — |
| 2023 | US$14.09M | — | -US$182.97M | -US$176.94M | — |
| 2022 | US$102.69M | — | -US$3.56M | -US$22.63M | — |
| 2021 | — | — | -US$34.98M | -US$41.78M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$3.70M | -US$64.14M | — |
| 2026-03-31 | US$3.04M | -US$48.44M | — |
| 2025-12-31 | US$0.03M | -US$74.92M | — |
| 2025-09-30 | US$0.35M | -US$72.00M | — |
| 2025-06-30 | US$19.14M | -US$17.36M | — |
| 2025-03-31 | US$2.98M | -US$39.53M | — |
| 2024-12-31 | US$12.77M | -US$92.18M | — |
| 2024-09-30 | US$29.11M | -US$16.65M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.